# Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations

> **NCT07711210** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Jiangsu Aidea Pharmaceutical Group Co., Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** ACC017
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07711210
- **Lead sponsor:** Jiangsu Aidea Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-21
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07711210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07711210, "Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07711210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*